

A peer-reviewed version of this preprint was published in PeerJ on 12 July 2019.

[View the peer-reviewed version](https://doi.org/10.7717/peerj.7325) (peerj.com/articles/7325), which is the preferred citable publication unless you specifically need to cite this preprint.

Morenikeji OB, Thomas BN. 2019. In silico analyses of CD14 molecule reveal significant evolutionary diversity, potentially associated with speciation and variable immune response in mammals. PeerJ 7:e7325 <https://doi.org/10.7717/peerj.7325>

***In silico* analyses of CD14 molecule reveals significant evolutionary diversity potentially associated with speciation and variable immune response in mammals**

Olanrewaju B Morenikeji¹, Bolaji N Thomas^{Corresp. 1}

¹ Biomedical Sciences, Rochester Institute of Technology, Rochester, NY, United States of America

Corresponding Author: Bolaji N Thomas

Email address: bntsbi@rit.edu

Cluster differentiation gene (CD14) is a family of monocyte differentiating genes that works in conjunction with lipopolysaccharide binding protein (LBP), forming a complex with TLR4 or LY96 to mediate innate immune response to pathogens. In this paper, we used different computational methods to elucidate the evolution of CD14 gene coding region in 14 mammalian species. Our analyses identified leucine rich repeats (LRRs) as the only significant domain across the CD14 protein of the 14 species, presenting with frequencies ranging from 1-4. Importantly, we found signal peptides located at mutational hotspots demonstrating this gene is conserved across these species. Out of the 10 selected variants analyzed in this study, only 6 were predicted to possess significant deleterious effect. Our predicted protein interactome showed a significant varying protein-protein interaction with CD14 protein across the species. This may be important for drug target and therapeutic manipulation for the treatment of many diseases. We conclude that these results contribute to our understanding of the CD14 molecular evolution, which underlays varying species response to complex disease traits.

***In silico* analyses of CD14 molecule reveals significant evolutionary
diversity potentially associated with speciation and differential
immune response in mammals**

Olanrewaju B. Morenikeji, Bolaji N. Thomas

Department of Biomedical Sciences, Rochester Institute of Technology, Rochester NY

Olanrewaju B. Morenikeji: obmhst@rit.edu

Bolaji N. Thomas: bntsbi@rit.edu

***Corresponding author:**

Dr. Bolaji N. Thomas

Department of Biomedical Sciences

Rochester Institute of Technology

153 Lomb Memorial Drive

Rochester NY 14623

Office: (585) 475-6382

Fax: (585) 475-5809

Email: bntsbi@rit.edu

Abstract

Cluster differentiation gene (CD14) is a family of monocyte differentiating genes that works in conjunction with lipopolysaccharide binding protein (LBP), forming a complex with TLR4 or LY96 to mediate innate immune response to pathogens. In this paper, we used different computational methods to elucidate the evolution of CD14 gene coding region in 14 mammalian species. Our analyses identified leucine rich repeats (LRRs) as the only significant domain across the CD14 protein of the 14 species, presenting with frequencies ranging from 1-4. Importantly, we found signal peptides located at mutational hotspots demonstrating this gene is conserved across these species. Out of the 10 selected variants analyzed in this study, only 6 were predicted to possess significant deleterious effect. Our predicted protein interactome showed a significant varying protein-protein interaction with CD14 protein across the species. This may be important for drug target and therapeutic manipulation for the treatment of many diseases. We conclude that these results contribute to our understanding of the CD14 molecular evolution, which underlays varying species response to complex disease traits.

Keywords: CD14, mammals, species, immune response, evolution, *in silico*

Introduction

Cluster of differentiation 14 (CD14) gene is a surface differentiation antigen preferentially expressed on mammalian monocytes, neutrophils, macrophages, and plasma cells (Baumann *et al.*, 2010; Tang *et al.*, 2017). It encodes a protein that is important for initiating a robust immune response against microbial pathogens by mediating innate immune response, in concert with several other proteins. It is a co-receptor with Toll-like receptor-4 (TLR4) to activate several intracellular signaling pathways that lead to the synthesis and release of inflammatory cytokines, antimicrobial peptides, chemokines, and other co-stimulatory molecules, which in turn interact with the adaptive immune system (Hartel *et al.*, 2008). Comparative studies have shown that two or more proteins can have common evolutionary origin thereby sharing structural and functional characteristics (Kanduc, 2012). CD14 molecule exists in two forms: soluble (sCD14) or membrane-bound (mCD14) (Panaro *et al.*, 2008; Xue *et al.*, 2012). There are multiple variants of the CD14 molecule that are encoded by the same protein due to alternative splicing and as such has been mapped to varying chromosomal locations in different species. For example, it is mapped to chromosome 5 in humans, chromosome 7 in cattle and chromosome 18 in mouse (Ferrero *et al.*, 1990; Le Beau *et al.*, 1993; Ibeagha-Awemu *et al.*, 2008).

Studies in human, mouse, cattle and sheep have shown that CD14 is significantly involved in innate immunity, playing major roles in susceptibility to tuberculosis, trypanosomosis, malaria and other bacterial infections (Sugawara *et al.*, 2003; Ibeagha-Awemu *et al.*, 2008; Xue *et al.*, 2012; Ojurongbe *et al.*, 2017). Other published reports have shown that there is a higher susceptibility to *Mycobacterium tuberculosis* infection in CD14 transgenic mice compared to the wild type (Reiling *et al.*, 2002; Weiland *et al.*, 2008). Likewise, single nucleotide polymorphisms

(SNPs) in CD14 gene have been associated with higher susceptibility in many disease instances (Oakley *et al.*, 2009; Liu *et al.*, 2012; Xue *et al.*, 2012; Zanoni and Granucci, 2013; Thomas *et al.*, 2015; Xue *et al.*, 2017). In fact, Song *et al.* (2014) reported how genetic heterozygosity modulate disease resistance and progression in cattle infected with bovine tuberculosis. Furthermore, comparative studies have shown that organism relatedness can be traced through their pattern of genetic divergence (De Donato *et al.*, 2017; Peters *et al.*, 2018).

Several sequence-based methods and tools have been developed to glean evolutionary information in related species via amino acid sequence variation and conservation of homologous proteins through multiple sequence alignment (MSA) (Hepp *et al.*, 2015, Peters *et al.*, 2018). Similarly, other computational methods are available to identify SNP variation within and between amino acid sequences in multiple species, possibly affecting the stability and functionality of such proteins (Ng and Henikoff, 2006; Yue and Moulton 2006; Hepp *et al.*, 2015). Many of these tools can predict the effect of SNP occurrence in protein sequences to determine whether they are disease related, deleterious or neutral. Comparative genomics therefore is a powerful tool to elucidate variants and effects among species in order to detect diseases associated with variations. Variations in amino acid sequence have the ability to alter protein structure and functions like ligand binding, protein folding, impaired intracellular transport and reduced stability (Zeron-Medina *et al.*, 2013; Morisseau *et al.*, 2014; Valastyan and Lindquist 2014).

Due to the significance of CD14 gene in several disease cases in humans and other species, in addition to its considerable involvement in innate immunity, we hypothesize that there might be

evolutionary patterns of similarity and diversification that occurred during speciation, which is important for comparative immune and disease studies in different species. To this end, we carried out a detailed comparative study of CD14 protein in 14 mammalian species to elucidate the evolutionary basis for conserved regions, active sites and mutational hotspots, which could lead to novel disease phenotypes. In addition, we examine the diversification in CD14 protein interactions within and across the species, which could be explored for therapeutic development or drug design.

Materials and Methods

Sequence retrieval and multiple sequence alignment

Complete CD14 amino acid sequences of 13 mammals were retrieved from UniProtKB/Swiss-Prot (<https://www.uniprot.org/uniprot/?query=CD14&sort=score>) database. The sequences were retrieved for human (P08571), rat (Q63691), mouse (P10810), cattle (Q95122), rabbit (Q28680), monkey (B3Y6B8), gorilla (G3R4C0), sheep (W5QJA2), horse (F6VK89), pig (A7BG66), buffalo (A0A2R4SDF9), chimpanzee (B3Y6B4) and yak (L8I9P7). The amino acid sequence for goat (ABE68725.1) was retrieved from GenBank. We performed sequence alignment with the Multalin software (<http://multalin.toulouse.inra.fr/multalin/>), which does a simultaneous alignment of biological sequences with hierarchical clustering. To examine similarity between the sequences, we used SIAS (Sequence Identity And Similarity, <http://imed.med.ucm.es/Tools/sias.html>) with default BLOSUM62 scoring matrices. Evolutionary tree was constructed from the sampled species through Phylogeny.fr (<http://www.phylogeny.fr/index.cgi>) online program.

Comparative physicochemical properties of amino acid sequence in the CD14 molecule

The biochemical properties of the amino acids from the 14 mammalian species were computed with ProtParam (www.expasy.org/protparam/). The following properties were computed for each sequence: aliphatic index, which defines the relative volume of a protein occupied by alanine, valine, isoleucine, and leucine; instability index, which estimates the protein stability based on the amino acid composition; protein net charge, which can be positive, negative or neutral based on the amino acid composition in the protein; molecular weight; grand average of hydropathicity (GRAVY), which determines the hydrophobicity of a protein from the aliphatic side chain; and isoelectric point (pI), which is the pH at which the protein net charge is equal to zero.

Functional analysis, motif scanning and prediction of signal peptides

We performed functional analysis on the protein sequences in order to classify them into superfamilies, predict domains, repeats and find important sites that may be relevant in evolution. We scanned for motif signatures among amino acid sequences with the combined use of ScanProsite (<https://prosite.expasy.org/>) (Sigrist *et al.*, 2010) and InterPro, an online program that analyzes protein sequences and classification (<https://www.ebi.ac.uk/interpro/>). The HAMAP profiles, PROSITE patterns, Pfam global models and PROSITE profiles were all included in the search. Sequence logo of the identified conserved domain in the CD14 protein among the 14 mammalian species was constructed with WebLogo (<http://weblogo.berkeley.edu/logo.cgi>), to show the graphical view of the region containing the conserved amino acid among the species. Furthermore, we predicted the cleavage sites and the presence of signal peptides in CD14 protein from the 14 mammalian species using SignalP 5.0 server (<http://www.cbs.dtu.dk/services/SignalP/>), which uses recurrent neural network

architecture and deep convolution to classify signal peptides into lipoprotein signal peptides, secretory signal peptides or Tat signal peptides. In order to gain a better understanding of the localization of the protein in each species, we predicted subcellular localizations of CD14 protein using Neural Networks algorithm on DeepLoc-1.0 server (<http://www.cbs.dtu.dk/services/DeepLoc/>), and the construction of the subcellular pathway hierarchical tree.

Prediction analysis of amino acid substitution

The effect of the amino acid substitution was predicted using the combination of SIFT (Sorting Intolerance from Tolerance), PANTHER (Protein ANalysis THrough Evolutionary Relationship) and PROVEAN (Protein Variation Effect Analyzer). Briefly, we used human CD14 amino acid sequence to query the multiple sequence alignment of other mammalian species in this study using SIFT, which predict the tolerance or deleterious effect of substitutions for each position in the query sequence. Any position with probability less than 0.05 is classified as deleterious, as previously described (Bendl *et al.*, 2014; Choi and Chan 2015). We selected a total of 10 variants from the mutational hotspots as predicted by SIFT and further estimate the likelihood of the selected variants and their effects on protein function through PROVEAN and PANTHER.

Prediction of protein interactome with CD14 protein in different species

In order to establish specific interaction of the CD14 protein with other molecules as a result of biochemical events during speciation, we used the retrieved CD14 amino acid sequence from each mammalian species to predict its association with other protein groups and generate different networks using STRING, a database that predicts protein-protein interactions (<https://string->

db.org/). This is important in order to examine the diversity shaped by evolution in the association of CD14 gene with other molecules in different organisms. Venn diagrams were constructed for the comparison and visualization of overlapping protein-protein interaction (PPI) among different species using two web-based applications (<http://bioinformatics.psb.ugent.be/software/details/Venn-Diagrams> and <http://bioinfogp.cnb.csic.es/tools/venny/>)

Results

Comparative analysis and sequence evolutionary trace

In this study, we examined the evolutionary pattern of CD14 protein sequences in 14 mammalian species. The alignment is conserved within two groups separated into ruminants and non-ruminants. The multiple sequence alignment identified leucine (L), aspartic acid (D), lysine (K), glutamic acid (E), valine (V), glycine (G), serine (S) and asparagine (N) as evolutionarily conserved amino acid residues, while others like proline (P), glutamine (Q), methionine (M), alanine (A), phenylalanine (F), isoleucine (I) and threonine (T) were evolutionarily varied. The CD14 protein sequence demonstrates significant variability in both percentage identity and similarity across the 14 species, despite the common evolutionary origin (Figure 1, 2). The percentage identity of CD14 protein in monkey, gorilla, chimpanzee and human was similar while gorilla shares the closest identity with human (Table 1). Among the ruminants, cattle and yak share the closet similarity compared to buffalo, sheep and goat, although the phylogenetic tree suggests that goat is distantly related. While mouse and rat cluster with the same origin, the analysis shows that they share less identity (7.4%) and similarity (13.4%). Rabbit, horse and pig are distantly apart from other species, as they do not share high conservation (Table 1, Figure 2).

In all, the sequence of CD14 protein in goat and horse share the least identity (6.7% and 6.9% for goat and horse respectively) and similarity (9.9% and 13.2% for goat and horse respectively) with human.

Physicochemical properties at the CD14 promoter region

ProtParam tool (www.expasy.org/protparam/) was used to compute the physical and chemical properties of CD14 amino acid sequences among the 14 species (Table 2). The aliphatic index is generally high for all species showing that the protein is thermally stable. A higher instability index was observed in the CD14 molecule of rabbit, pig and monkey (53.0, 46.8 and 45.1 respectively), indicating that the protein is less stable and hydrophobic amino acids, such as leucine, valine, serine and asparagine, occupy majority of the sequence, providing higher tolerance against diseases. The lowest instability index is observed in horse (33.5) and goat (35.1) showing that the protein is more stable in these species. The CD14 protein in goat also has the lowest aliphatic index (99.7) while mouse has the highest (107.7). We observed a closer range of molecular weight among the species in this study, although gorilla, monkey, human, chimpanzee and rat had the higher molecular weight with close range (Table 2). Negative net charge, indicative that the protein is more basic than acidic, ranged from -9 as found in mouse and rat to +4 as found in goat. Goat, horse and gorilla has higher isoelectric point (Ip) indicating that CD14 molecule is highly basic in these species than others. The GRAVY values obtained were generally positive and higher in ruminants than non- ruminants, suggesting the proteins are more hydrophobic, which enhances oligomerization and higher binding capability to different proteins.

Characterization of functional motifs and prediction of signal peptides

The CD14 amino acid sequences of the 14 mammalian species in this study were individually scanned for matches against the InterPro and PROSITE collection of protein signature databases. We found one domain (Leucine-rich repeat (LRR), PS51450) with varying frequency across the 14 species (Figure 3). Comparison of the predicted intra-domain features show one LRR domain in human, two each in gorilla, chimpanzee, monkey, horse and pig, three each in cattle, sheep, buffalo, yak, and mouse, with the highest number (4) found in rat. Figure 4 shows the multiple sequence alignment of the homology of LRR domain across the 14 species, showing that leucine, aspartic acid, serine and asparagine are 100% conserved in this region. The sequence logo built from the multiple sequence alignment of the domain is displayed in Figure 5, with the logo showing the relative frequencies of each conserved amino acid and their position in the LRR domain. The domain homology reveals that there is significant conservation of most amino acids in this region.

Furthermore, we predicted the signal peptides, position and secretory pathway of the CD14 amino acids in the 14 species under consideration. Our analysis show that chimpanzee, gorilla, human and monkey share the same signal peptide (VSA-TT) at the same position (19 and 20), with high likelihood (Table 3). Buffalo, cattle, sheep and yak also share the same signal peptide (VSA-DT) and position (20 and 21), although sheep has a different position (19 and 20). We observed a significant variation for the rest of the species in terms of signal peptides and their positions (Table 3). Interestingly, signal peptide for all the species (Figure 6a), except sheep (Figure 6b), share the same subcellular localization in the neural network.

230 ***Mutational analysis of predicted variation***

231 A total of 10 variants were selected from the predicted mutations by SIFT and the effects were
232 tested as deleterious or not in the 14 species with PROVEAN and PANTHER. Our analysis
233 showed that 4 of these variants (D28V, W45H, G62E, L70D) were validated mutations with
234 deleterious effect on all species with 2 others found in few species. These variants cluster in the
235 C-terminus region of CD14 protein between 20 to 100 amino acids. A closer look suggests that
236 mutational effect on the CD14 protein sequence varied from C-terminus to N-terminus with less
237 mutational effect towards the N-terminus (Table 4). The deleterious mutations observed in our
238 study were all at the C-terminus region thus identifying it as a mutational hotspot. Q100G,
239 V301M, L318I, G335T, L357H and G370K mutation spots were neutral for most species. This
240 might mean that CD14 is less conserved in this region because of evolutionary divergence of all
241 species. However, L-H at position 357 showed a deleterious effect in cattle, yak, pig, gorilla,
242 human, monkey, buffalo and chimpanzee, while there is also a deleterious effect of G-K at
243 position 370 of CD14 in rat.

244

245 ***Protein-protein interaction cluster with CD14 gene in different species***

246 In order to deduce protein-protein interactions (PPI) that evolved through speciation due to co-
247 localization, additive genetic interaction, co-expression or repression and physical association
248 with CD14 in the mammalian species under study, we used STRING to build the protein
249 network, based on collection of laboratory experimental results from the database (Figure 7) and
250 segment the gene pool base on our phylogenetic result to build Venn diagrams for each species
251 cluster (Figure 8a, b, c). We could not find any protein network for horse and so was excluded in
252 the analysis. Our result shows that there is significant variation in the CD14 protein interactome

across species (Figure 7). Generally, we found that there were different proteins that clustered with CD14 in all the species. All species had 10 proteins in their cluster except cattle and goat that had 11. Looking at the Venn diagram, rabbit had the highest CD14 PPI that is not shared with others while 3 protein set (CD14, TLR2 and TLR4) is common to members of this group (Figure 8a). Figure 8b shows the ruminant group, including goat, sheep and yak had no unique gene set, meaning the PPI is duplicated in one or two other members of the group. However, cattle has 8 unique PPI while buffalo has 4, that were not shared with others. CD14 and TLR2 are common to all in this group. Likewise, there were 8 unique PPI in human, 6 in gorilla and none in monkey and chimpanzee (Figure 8c).

Discussion

Comparative analysis of CD14 protein in this study enhances our understanding of genome plasticity among 14 mammalian species and establishes functional, molecular and structural relationships in different clades that are important in an evolutionary trace. The significant variability in the multiple sequence alignment of CD14 molecule across the species suggests a high evolutionary divergence especially between the ruminant and non-ruminant group. This implies that CD14 amino acid sequence had undergone significant changes during speciation leading to functional and structural modification in different species. Studies have shown that variation in amino acid sequences could impact immunogenicity, immunotolerance and immunoreactivity (Tauber, 2004, Kanduc, 2012; Bendl *et al.*, 2014). However, we found that amino acid residues like leucine (L), glutamic acid (E), lysine (K), valine (V), aspartic acid (D), glycine (G), serine (S) and asparagine (N) are highly conserved, thereby retaining some degree of homology in functional, molecular and structural characteristics. In addition, this reveals the

common origin between the mammalian species before divergent speciation. Based on the percentage identity and similarity, monkey, gorilla and chimpanzee are closer to human in their CD14 amino acid sequence, suggesting a lower degree of variation and may infer some degree of similar CD14 expression during disease condition (Ferrero *et al.*, 1990; Ibeagha-Awemu *et al.*, 2008; Bendl *et al.*, 2014).

We also observed that the molecular weight, isoelectric point (Ip), instability index and net charge of CD14 protein for this group of mammals are similar, suggesting a key biochemical and immunological function is retained in these species during evolution (Saha *et al.*, 2013; Ajayi *et al.*, 2018). Of interest, the CD14 sequence in cattle and buffalo were much more conserved than yak, despite their common origin potentially implying that domestication has not affected key biological functions in cattle, and the possibility that buffalo can also be domesticated without loss of immunological function. Furthermore, a higher aliphatic index, net negative charge and GRAVY as shown in the physicochemical properties of CD14 protein in mouse and rat gives an indication of high concentration of alanine, valine, isoleucine and leucine, reported to influence transcription factors, providing higher tolerance against bacterial and viral infections (Korber, 2000; Panaro *et al.*, 2008; Ivanov *et al.*, 2015). This is thought to be an important evolutionary adaptation for these small animals to survive bouts of exposure to diseases in their environment, and may explain the basis for these organisms at times serving as reservoir hosts for many disease pathogens in humans. The general negative net charge of CD14 protein as observed across the species indicates an increasing reactivity and help in its receptor binding mechanism. Therefore, the higher the net charge, the more the reactivity of the protein.

Interestingly, our motif and signal peptide scan found just one domain and one signal peptide in the entire length of CD14 amino acid sequence. The numbers of conserved leucine-rich repeat (LRR) domains vary from species to species. Species with similar number of LRR profile may likely have same immunological implications. This again, is a significant evolutionary signature. CD14 is a co-receptor that bind with LPS, therefore a higher leucine amino acid profile in the molecule may accelerate its binding mechanism to receptor in a significant way because the protein plays a significant regulatory role in initiating a robust innate immune response. Studies have shown that LRR domain is evolutionarily conserved in most of the innate immune related proteins in vertebrates, invertebrates and plants, providing the innate immune defense especially through pathogen-associated molecular patterns (PAMPs) (Aylwin and Ramnik 2011). Some reports also stated that there about 2–45 leucine-rich repeats within the LRR domain, containing up to 30 residues. Classifying our mammalian species under study into ruminants versus non-ruminants, we observed that non-ruminants possess a lower number of LRR domain in their CD14 molecule (one domain in human, three in ruminants and four in rat). Notably, rat again possesses the highest number of LRR domains remarkably traceable to selection pressure across the species. Moreover, the amino acid sequence of this domain is highly conserved for all species under study, and are found towards the C-terminal region of CD14, justifying the fact that amino acid sequence variation that differentiate species are found close to the N-terminal region (Peters *et al.*, 2018).

Our study additionally reveals varying secretory signal peptide sites in the CD14 molecule across the species. Signal peptides have been identified as hydrophobic amino acids, recognized by the signal recognition particle (SRP) in the cytosol of eukaryotic cells. Secretory signal peptide is a

class of signal peptide that allows the export of a protein from the cytosol into the secretory pathway (Nielsen and Krogh, 1998; Park and Kanehisa, 2003; Rivas and Fontanillo, 2010; Sigrist *et al.*, 2010). In this, we found that human, monkey, gorilla and chimpanzee all have the same signal peptide site and position. Cattle, yak, sheep and buffalo also share the same site and position whereas goat did not, confirming why goat is significantly distant to other ruminants in our phylogenetic construction. It is unclear if this is related to disease tolerance when compared to other species. However, we noted in our predicted neural network that the subcellular localization of CD14 protein goes from the extracellular through the intracellular and enters the secretory pathway for all the species, except sheep. In sheep, the subcellular localization begins from the nucleus through the mitochondrion, peroxisomal targeting signal (PTS) and N-terminal sequences before it enters into the secretory pathway. This information may possess potential immunological consequences that will require further analysis and possibly an *in-vitro* validation.

Of most importance, a higher proportion of the predicted mutations occupying the C-terminal region of CD14 protein show that they are closer to the active site and may have direct structural and functional effects on the protein thereby causing harmful disease phenotype or susceptibility (Malm and Nilssen, 2008). Studies have shown that the leucine-rich repeats at the C-terminal region is required for responses to smooth lipopolysaccharide, whereas the variable region (290 – 375) has been found to be necessary for response to bacterial lipopolysaccharide (Bella *et al.*, 2008; Arnesen, 2011; Xue *et al.*, 2012, 2018). Therefore, variation at this region might be traceable to varied exposure and responses to pathogens in the cause speciation.

We observed a higher proportion of deleterious mutational spots in human, monkey, gorilla and chimpanzee occupying the same loci compared to ruminants and other species. This might suggest that the vital residue conservation at this region is due to selection pressure among these species and has been maintained over time possibly because of their role in evolution, resulting in similar biological and immunological function (Feder and Mitchell-Olds, 2003; De Donato et al., 2017; Peters et al., 2018). Therefore, a perturbation of the amino acid sequence at this region could affect protein folding, ligand binding and other functions, which might be lethal or regarded as disease-causing mutation in all mammals. Understanding the molecular variation in the region could help solve the challenge of Mendelian disease phenotypes. We recommend an *in vitro* study of this region in CD14 protein sequence to elucidate the molecular mechanism affecting functionality of this region. In all, 3 of these mutations have been characterized and verified in humans to cause disruption of active site and loss of protein activities (Hidam and Debasish, 2018).

Furthermore, we used the STRING database to annotate CD14 protein network with other protein molecules that may have evolved together during speciation. Significantly, we found that CD14 molecule selectively interact with other proteins from species to species. For example, in cattle, CD14 molecule interacts with 8 other proteins, which are not shared with goat, sheep and yak. In a similar vein, buffalo has 4 unique sets of protein that co-express with CD14 protein. Human and gorilla in their group has 8 and 6 genes respectively that uniquely interact with CD14 protein, which are not found in monkey and chimpanzee. These protein interactions are possibly due to the specific molecular or biochemical changes that occur in CD14 protein during selection pressure in different species. This interactome is important to decipher molecular and

biochemical mechanisms shaped by evolution, which may be useful for drug design and therapeutic treatment of many diseases. Several studies have shown that molecular association between chains of different protein molecules is geared by the electrostatic force like hydrophobic effects which define specific bimolecular interaction in different organism (Arkin *et al.*, 2014; De Las and Fontanillo, 2010; Chen *et al.*, 2013). The modulation of this interaction may be useful as putative therapeutic targets for disease treatment in many species. Ivanov *et al* (2013) have used the interaction of Tirobifan with glycoprotein IIb/IIIa as an inhibitor for cardiovascular drug discovery, likewise the interaction of Maraviroc and CCR5-gp120 for anti-HIV drug.

As shown earlier, there are variations in the number of the LRR domain among these species, possibly the lesser number of LRR domain in human is supplemented or accounted for by the functionality of other genes in the network (Thakur and Shankar, 2016). From our physicochemical properties, CD14 is classified as hydrophobic across the species due to higher proportion of LRR. The varying degree of LRR among these species is thought to affect the electrostatic force created by the hydrophobic effects of the protein. Published studies have shown that diverse fungal, bacterial, viral and parasite components are sensed by the mammalian LRR domain of proteins like NOD-like receptors and Toll-like receptors (Korber, 2000; Kutay and Guttinger, 2005; Lucchese *et al.*, 2009; Kamaraj and Purohit 2014). Likewise, about 34 leucine-rich repeat proteins have been associated with diseases in human. Obviously, divergent evolutionary events have shaped the protein-protein interaction of CD14 in different species, which is thought to be significant to varying degrees of disease susceptibility and pathogen selection.

391

392 **Conclusion**

393 We have used computational methods to gather information on CD14 protein in 14 mammals.
394 Our *in silico* comparison of CD14 amino acid sequences among these species gave molecular
395 evidence of a divergent evolutionary events that occurred during speciation, potentially of
396 significance in modulating innate immune response to pathogenic challenges. Obviously, this
397 gene has been subjected to selection pressure due to sufficient sequence variation we found from
398 one species to another. We identified mutational hotspots with damaging effects in human and
399 other species. In particular, the signal peptides located in these mutational hotspots are possibly
400 of major importance in immunological studies. The variants identified in this study can be
401 further subjected to validation through *in vitro* analysis. Since CD14 molecule is essential in
402 initiating proper immune response to pathogens and the precursor of a robust adaptive immune
403 response, our study highlights the effect of mutations on protein structure and disease outcome,
404 protein-protein interaction that may be essential for drug design, yielding themselves to
405 therapeutic manipulations for treating many diseases. Finally, these results contribute to our
406 understanding of the evolutionary mechanism that underlie species variation in response to
407 complex disease traits.

408

409 **Acknowledgement**

410 This work was funded by a Laboratory and Faculty Development Award, College of Health
411 Sciences and Technology, Rochester Institute of Technology (BNT). OBM is supported through
412 the American Association of Immunologists Careers in Immunology Fellowship Program. The

funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

- Ajayi OO, Peter SO, De Donato M, Mujibi FD, Khan WA, Hussain T, Babar ME, Imumorin IG, Thomas BN. 2018.** Genetic variation in N- and C-terminal regions of bovine DNAJA1 heat shock protein gene in Africa, Asian and American cattle. *Journal of Genomics*. **6**:1-8. doi: 10.7150/jgen.23248
- Arkin MR, Tang Y, Wells JA. 2014.** Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. *Cell Chemical Biology* **3**:301-17. DOI:10.1016/j.chembiol.2014.09.001
- Arnesen, T. 2011.** Towards a functional understanding of protein N-terminal acetylation. *PLoS Biology*, **9**(5):e1001074. doi:10.1371/journal.pbio.100107
- Bella J, Hindle KL, McEwan PA, Lovell SC. 2008.** The leucine-rich repeat structure. *Cell Molecular Life Science*. **65**: 2307-2333. 10.1007/s00018-008-8019-0
- Bendl J, Stourac J, Salanda O, Pavelka A, Wieben ED, Zendulka J, Brezovsky J, Damborsky J. 2014.** PredictSNP: Robust and Accurate Consensus Classifier for Prediction of Disease-Related Mutations. *PLoS Computational Biology*. **10**: e1003440. doi: 10.1371/journal.pcbi.1003440 PMID: 24453961
- Bendl J, Stourac J, Salanda O, Pavelka A, Wieben ED, Zendulka J, Brezovsky J, Damborsky J. 2014.** PredictSNP: robust and accurate consensus classifier for prediction of disease-related mutations. *PLoS Computational Biology* **10**: e1003440.

- 435 **Chen S, Krinsky BH, Long M. 2013.** New genes as drivers of phenotypic evolution. *Nature*
436 *Reviews Genetics*. **14**:645-60. doi: 10.1038/nrg3521.
- 437 **Choi Y, Chan AP. 2015.** PROVEAN web server: a tool to predict the functional effect of amino
438 acid substitutions and indels. *Bioinformatics* **31**:2745–7.
- 439 **Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. 2012.** Predicting the Functional Effect of
440 Amino Acid Substitutions and Indels. PLoS ONE. **7**: e46688. doi:
441 10.1371/journal.pone.0046688 PMID: 23056405
- 442 **De Donato M, Peters SO, Hussain T, Rodulfo H, Thomas BN, Babar ME, Imumorin IG.**
443 **2017.** Molecular evolution of type II MAGE genes from ancestral MAGED2 gene and
444 their phylogenetic resolution of basal mammalian clades. *Mammalian Genome* **28**:443–
445 54.
- 446 **Dultz E, Hildenbeute M, Martoglio B. Hochman J, Dobberstein B, Kapp K. 2008.** The
447 signal peptide of the mouse mammary tumor virus Rem protein is released from the
448 endoplasmic reticulum membrane and accumulates in nucleoli. *Journal of Biological*
449 *Chemistry*. **283**:9966–76. DOI:10.1074/jbc.M705712200
- 450 **Feder ME, Mitchell-Olds T. 2003.** Evolutionary and ecological functional genomics. *Nature*
451 *Reviews Genetics* **4**:651-7. DOI:10.1038/nrg1128
- 452 **Ferrero E, Hsieh C L, Francke U, Goyert SM. 1990.** CD14 is a member of the family of
453 leucine-rich proteins and is encoded by a gene syntenic with multiple receptor genes.
454 *Journal of Immunology* **145**:331-336
- 455 **Härtel C, Rupp J, Hoegemann A, Bohler A, Spiegler J, von Otte S, Röder K, Schultz C,**
456 **Göpel, W. 2008.** 159C >T CD14 genotype-functional effects on innate immune
457 responses in term neonates. *Human Immunology* **69**: 338–343

- 458 **Hepp D, Gonçalves GL, de Freitas TR. 2015.** Prediction of the Damage-Associated Non-
459 Synonymous Single Nucleotide Polymorphisms in the Human MC1R Gene. *PLoS ONE*
460 **10:** e0121812. doi:10.1371/journal.pone.0121812
- 461 **Hidam B and Debasish B.** In silico assessment of human CD14 gene revealed high-risk single
462 nucleotide polymorphisms and their impact on innate immune response against
463 microbial pathogens. *Meta Gene* 2018;17. DOI: 10.1016/j.mgene.2018.05.010
- 464 **Huyen Y, Jeffrey PD, Derry WB, Rothman JH, Pavletich NP, Stavridi ES, Halazonetis TD.**
465 **2004.** Structural differences in the DNA binding domains of human p53 and its C.
466 elegans ortholog Cep-1. *Structure*.**12**:1237–1243.
- 467 **Ibeagha-Awemu EM, Lee JW, Ibeagha AE, Zhao X. 2008.** Bovine CD14 gene
468 characterization and relationship between polymorphisms and surface expression on
469 monocytes and polymorphonuclear neutrophils. *BMC Genetics* **9**:50.
- 470 **Ivanov SM, Lagunin AA, Pogodin PV, Filimonov DA, Poroikov VV. 2014.** Identification of
471 drug-induced myocardial infarction-related protein targets through the prediction of
472 drug-target interactions and analysis of biological processes. *Chemical Research in*
473 *Toxicology*. **27**: 1263–1281.
- 474 **Ivanov SM, Lagunin AA, Pogodin PV, Filimonov DA, Poroikov VV. 2015.** Identification of
475 Drug Targets Related to the Induction of Ventricular Tachyarrhythmia Through a
476 Systems Chemical Biology Approach. *Toxicological Sciences*, **145**: 321–336. doi:
477 10.1093/toxsci/kfv054
- 478 **Käll L, Krogh A, Sonnhammer EL. 2004.** A combined transmembrane topology and signal
479 peptide prediction method. *Journal of Molecular Biology* **338**:1027–1036.

- 480 **Kamaraj B, Purohit R. 2013.** In silico screening and molecular dynamics simulation of disease-
481 associated nsSNP in TYRP1 gene and its structural consequences in OCA3. *Biomedical*
482 *Research International* 697051. doi: 10.1155/2013/697051 PMID: 23862152
- 483 **Kamaraj B, Purohit R. 2014.** Computational Screening of Disease-Associated Mutations in
484 OCA2 Gene. *Cell Biochemistry and Biophysics*. **68**: 97–109. doi: 10.1007/s12013-013-
485 9697-2 PMID: 23824587
- 486 **Kanduc D. 2012.** Homology, similarity, and identity in peptide epitope immunodefinition.
487 *Journal of Peptide Science* **18**: 487–494. DOI 10.1002/psc.2419
- 488 **Khan JM, Ranganathan S. 2009.** A multi-species comparative structural bioinformatics
489 analysis of inherited mutations in a-D-Mannosidase reveals strong genotype-phenotype
490 correlation. *BMC Genomics* **10**:S33 doi: 10.1186/1471-2164-10-S3-S33
- 491 **Korber B. 2000.** HIV signature and sequence variation analysis. In: Rodrigo Allen G, Learn
492 Gerald H., editors. Computational Analysis of HIV Molecular Sequences. Chapter 4.
493 Dordrecht, Netherlands: Kluwer Academic Publishers; pp. 55–72.
- 494 **Kutay U, Guttinger S. 2005.** Leucine-rich nuclear-export signals: born to be weak. *Trends Cell*
495 *Biology* **15**:121–4
- 496 **Liu H-H, Hu Y, Zheng M, et al. 2012.** *Cd14* SNPs regulate the innate immune
497 response. *Molecular Immunology*, **51**:112-127
- 498 **Lucchese A, Serpico R, Crincoli V, Shoenfeld Y, Kanduc D. 2009.** Sequence uniqueness as a
499 molecular signature of HIV-1-derived B-cell epitopes. *International Journal of*
500 *Immunopathology and Pharmacology* **22**: 639–646.
- 501 **Malm D, Nilssen Ø. 2008.** Alpha-mannosidosis. Orphanet Journal of Rare Disease. **23**:21. doi:
502 10.1186/1750-1172-3-21.

- 503 **Meng QJ, Master AM, Beesley S, Lu WQ, Gibbs J, Parks D, Collins J, Farrow S, Donn R,**
504 **Ray D, Loudon A. 2008.** Ligand modulation of REV-ERB α function resets the
505 peripheral circadian clock in a phasic manner. *Journal of Cell Sciences* **121**: 3629-3635;
506 doi: 10.1242/jcs.035048
- 507 **Meng X, Noyes MB, Zhu LJ, Lawson ND, Wolfe SA. 2008.** Targeted gene inactivation in
508 zebrafish using engineered zinc-finger nucleases. *Nature Biotechnology* **26**:695-701.
- 509 **Morisseau C, Wecksler AT, Deng C, Dong H, Yang J, Lee KSS, Kodani SD, Hammock BD.**
510 **2014.** Effect of soluble epoxide hydrolase polymorphism on substrate and inhibitor
511 selectivity and dimer formation. *The Journal of Lipid Research*. **55**: 1131-1138. doi:
512 10.1194/jlr.M049718.
- 513 **Ng A, Xavier RJ. 2011.** Leucine-rich repeat (LRR) proteins: Integrators of pattern recognition
514 and signaling in immunity. *Autophagy* **7**: 9. <https://doi.org/10.4161/auto.7.9.16464>
- 515 **Ng PC, Henikoff S. 2006.** Predicting the effects of amino acid substitutions on protein function.
516 *Annu Rev Genomics Human Genetics*. **7**:61-80.
517 DOI:10.1146/annurev.genom.7.080505.115630
- 518 **Nielsen H, Krogh A. 1998.** Prediction of signal peptides and signal anchors by a hidden Markov
519 model. *Proc. Int. Conf. Intell. Syst. Molecular Biology* **6**:122–130
- 520 **Oakley MS, Majam V, Mahajan B, Gerald N, et al. 2009.** Pathogenic roles of CD14, galectin-
521 3 and OX40 during experimental cerebral malaria in mice. *PLoS ONE*, **4**(8):e6793
- 522 **Ojurongbe O, Funwei RI, Snyder T, Aziz N, Li Y, Falade C, Thomas BN. 2017.** Genetic
523 diversity of CD14 promoter gene polymorphism (rs2569190) is associated with
524 regulation of parasitemia but not susceptibility to *Plasmodium falciparum* infection.
525 *Infectious Diseases: Research and Treatment*, **10**:1-6. doi: 10.1177/1178633617726781.

- 526 **Panaro MA, Cianciulli A, Gagliardi N, Mitolo CI, Acquafredda A, Cavallo P, Mitolo V.**
- 527 **2008.** CD14 major role during lipopolysaccharide-induced inflammation in chick
- 528 embryo cardiomyocytes, *FEMS Immunology & Medical Microbiology*, **53**:35–45.
- 529 <https://doi.org/10.1111/j.1574-695X.2008.00397.x>
- 530 **Park KJ, Kanehisa M. 2003.** Prediction of protein subcellular locations by support vector
- 531 machines using compositions of amino acids and amino acid pairs. *Bioinformatics*
- 532 **19**:1656–1663.
- 533 **Peters SO, De Donato M, Hussain T, Rodulfo H, Babar ME and Imumorin IG. 2018.**
- 534 Sequence variation of necdin gene in Bovidae. *Journal of Animal Science and*
- 535 *Technology* **60**:32. <https://doi.org/10.1186/s40781-018-0191-7>
- 536 **Reiling N, Hölscher C, Fehrenbach A, Kröger S, Kirschning CJ, Goyert S, Ehlers S. 2002.**
- 537 Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in
- 538 resistance to airborne infection with Mycobacterium tuberculosis. *Journal of*
- 539 *Immunology* **169**:3480–3484
- 540 **Rivas JL, Fontanillo C. 2010.** Protein–Protein Interactions Essentials: Key Concepts to
- 541 Building and Analyzing Interactome Networks. *PLoS Computational Biology*.
- 542 <https://doi.org/10.1371/journal.pcbi.1000807>
- 543 **Saha R, Saha N, Donofrio RS, Bestervelt LL. 2013.** Microbial siderophores: a mini review.
- 544 *Journal of Basic Microbiology*. **53**: 303–317. <https://doi.org/10.1002/jobm.201100552>
- 545 **Sigrist CJA, Cerutti L, de Castro E, Langendijk-Genevaux PS, Bulliard V, Bairoch A,**
- 546 **Hulo N 2010.** PROSITE, a protein domain database for functional characterization and
- 547 annotation. *Nucleic Acids Research* **38**(Database issue):D161–D166

- 548 **Song Y, Sun L, Guo A, Yang L. 2014.** Toll-like receptor 6 gene polymorphisms increase the
- 549 risk of bovine tuberculosis in Chinese Holstein cattle. *Acta Histochemistry*. 116:1159-62.
- 550 doi: 10.1016/j.acthis.2014.06.004.
- 551 **Sugawara S, Yang S, Iki K, Hatakeyama J, Tamai R, Takeuchi O, Akashi S, Espevik T,**
- 552 **Akira S, Takada H. 2001.** Monocytic cell activation by Nonendotoxic glycoprotein
- 553 from *Prevotella intermedia* ATCC 25611 is mediated by toll-like receptor 2. *Infectious*
- 554 *Immunology* **69**:4951-4957. DOI: 10.1128/IAI.69.8.4951-4957.2001
- 555 **Tamura K, Stecher G, Peterson D, Filipinski A, Kumar S. 2013.** MEGA6: molecular
- 556 evolutionary genetics analysis version 6.0. *Molecular Biology Evolution* **30**:2725–2729
- 557 **Tang AT, Choi JP, Kotzin JJ, Yang Y, Hong CC, Hobson N, Girard R, Zeineddine HA,**
- 558 **Lightle R, Moore T, Cao Y, Shenkar R, Chen M, Mericko P, Yang J, Li L, Tanes C,**
- 559 **Kobuley D, Vösa U, Whitehead KJ, Li DY, Franke L, Hart B, Schwaninger M,**
- 560 **Henao-Mejia J, Morrison L, Kim H, Awad IA, Zheng X, Kahn ML. 2017.**
- 561 Endothelial TLR4 and the microbiome drive cerebral cavernous malformations. *Nature*.
- 562 **18**; 545(7654): 305–310. doi: 10.1038/nature22075
- 563 **Tauber E, Last KS, Olive PJ, Kyriacou CP. 2004.** Clock gene evolution and functional
- 564 divergence. *Journal of Biological Rhythms*, **19**:445– 458.
- 565 **Tauber E, Zordan M, Sandrelli F, Pegoraro M, Osterwalder N, Breda C, Daga A, Selmin**
- 566 **A, Monger K, Benna C, Rosato E, Kyriacou CP and Costa R. 2007.** Natural selection
- 567 favors a newly derived timeless allele in *Drosophila melanogaster*. *Science* **316**: 1895–
- 568 1898.
- 569 **Thakur R and Shankar J. 2016.** *In silico* analysis revealed high-risk single nucleotide
- 570 polymorphisms in human pentraxin-3 gene and their impact on innate immune response

- 571 against microbial pathogens. *Frontiers in Microbiology* 7:192. doi:
- 572 10.3389/fmicb.2016.00192
- 573 **Thomas BN, Donvito B, Cockburn I, Fandeur T, Rowe JA, Cohen JHM, Moulds JM. 2005.**
- 574 A complement receptor-1 polymorphism with high frequency in malaria endemic
- 575 regions of Asia but not Africa. *Genes and Immunity*. 6:31-36. doi:
- 576 10.1038/sj.gene.6364150
- 577 **Valastyan JS, Lindquist S. 2014.** Mechanisms of protein-folding diseases at a glance. *Disease*
- 578 *Model and Mechanism*. 7:9-14. doi: 10.1242/dmm.013474.
- 579 **Viriyakosol S, Kirkland TN. 1996.** The N-terminal half of membrane CD14 is a functional
- 580 cellular lipopolysaccharide receptor. *Infection and immunity* 64:653–656.
- 581 **Xue Y, Gao WN, Chen F, Ma BB, Zhou F, Hu ZG, Long T, Zhao ZQ. 2018.** CD14 gene
- 582 polymorphisms associated with increased risk of bovine tuberculosis in Chinese Holstein
- 583 cows. *The Veterinary Journal* 232:1–5. doi: 10.1016/j.tvjl.2017.11.015
- 584 **Xue Y, Zhao ZQ, Chen F, Zhang L, Li GD, Ma KW, Bai XF, Zuo YJ. 2012.** Polymorphisms
- 585 in the promoter of the CD14 gene and their associations with susceptibility to pulmonary
- 586 tuberculosis. *Tissue Antigens* 80: 437–443.
- 587 **Yue P, Moul J. 2005.** Identification and analysis of deleterious human SNPs. *Journal of*
- 588 *Molecular Biology*. 10:1263-74. DOI:10.1016/j.jmb.2005.12.025
- 589 **Zanoni I, Granucci F. 2013.** Role of CD14 in host protection against infections and in
- 590 metabolism regulation. *Frontiers in Cellular and Infection Microbiology* 3:1-6
- 591 **Zeron-Medina J, Wang X, Repapi E, Campbell MR, Su D, Castro-Giner F, Davies B,**
- 592 **Peterse EF, Sacilotto N, Walker GJ, Terzian T, Tomlinson IP, Box NF,**
- 593 **Meinshausen N, De Val S, Bell DA, Bond GL. 2013.** A polymorphic p53 response

594 element in KIT ligand influences cancer risk and has undergone natural selection. *Cell*.
595 10:410-22. doi:10.1016/j.cell.2013.09.017

596

597

Table 1(on next page)

Table 1. Percentage identity (similarity) of the CD14 protein across the mammalian species

Identity:Minimum: 6.61; Maximum: 99.2; Mean: 23.2603296703297; Standard deviation: 26.568543593553

Similarity:Minimum: 9.91; Maximum: 100; Mean: 32.5818367346939; Standard deviation: 30.994144850177

Table 1: Percentage identity (similarity) of the CD14 protein across the mammalian species

2														
Human	100 (100)													
Rat	23.1 (27.9)	100												
Mouse	10.4 (14.5)	7.4 (13.4)	100											
Bovine	8.3 (11.5)	10.2 (15.1)	10.9 (15.3)	100										
Rabbit	29.3 (33.6)	15.6 (21.5)	9.3 (15.0)	9.4 (13.4)	100									
Goat	6.7 (9.9)	9.9 (15.1)	9.6 (13.7)	87.4 (89.3)	10.2 (14.2)	100								
Monkey	95.2 (96.3)	23.1 (28.0)	10.7 (14.4)	8.6 (12.1)	29.0 (33.9)	6.9 (10.5)	100							
Gorilla	99.2 (99.5)	23.1 (28.0)	10.4 (14.2)	8.3 (11.5)	29.0 (33.6)	6.7 (9.9)	95.5 (96.3)	100						
Sheep	20.8 (26.4)	12.4 (17.0)	7.9 (13.9)	8.9 (10.8)	19.4 (25.3)	8.4 (10.8)	21.3 (27.0)	21.0 (26.4)	100					
Horse	6.9 (13.2)	11.3 (17.1)	7.7 (13.8)	8.8 (13.8)	8.3 (14.0)	8.8 (13.5)	6.6 (12.9)	6.9 (13.2)	6.9 (11.8)	100				
Pig	18.5 (23.3)	13.2 (19.1)	10.9 (14.5)	67.6 (71.6)	18.8 (23.1)	60.1 (64.9)	19.3 (23.6)	18.8 (23.3)	19.1 (22.9)	8.0 (13.2)	100			
Buffalo	8.0 (11.3)	9.9 (14.8)	10.7 (15.3)	96.5 (97.3)	9.4 (13.2)	86.1 (88.7)	8.3 (11.8)	8.0 (11.3)	8.9 (10.8)	8.5 (12.9)	66.8 (71.3)	100		
Chimp	98.9 (99.2)	23.1 (28.2)	10.9 (14.8)	8.6 (11.8)	29.0 (33.6)	6.9 (10.2)	95.2 (96.0)	99.2 (99.2)	21.0 (26.7)	6.9 (13.2)	19.0 (23.6)	8.3 (11.5)	100	
Yak	8.3 (12.0)	8.6 (14.2)	9.0 (12.3)	42.1 (45.3)	8.3 (14.0)	37.5 (42.1)	8.3 (12.3)	8.3 (12.0)	9.4 (13.2)	8.0 (14.0)	21.4 (26.5)	41.0 (44.5)	8.5 (12.3)	100
	Human	Rat	Mouse	Bovine	Rabbit	Goat	Monkey	Gorilla	Sheep	Horse	Pig	Buffalo	Chimp	Yak

3
Identity: Minimum: 6.61; Maximum: 99.2; Mean: 23.2603296703297; Standard deviation: 26.568543593553

4
Similarity: Minimum: 9.91; Maximum: 100; Mean: 32.5818367346939; Standard deviation: 30.994144850177

Table 2 (on next page)

Table 2. Physicochemical properties of the CD14 molecule across the mammalian species

1 Table 2: Physicochemical properties of the CD14 molecule across the mammalian species

Species	Amino acids size	Molecular weight (Da)	Isoelectric point	Instability index	Aliphatic index	Net charge	GRAVY
Chimpanzee	375	40135.34	5.92	43.44	104.61	-4	0.113
Gorilla	375	40005.15	6.10	42.27	102.80	-3	0.094
Human	375	40076.20	5.84	42.93	101.76	-5	0.083
Monkey	375	40127.19	5.69	45.10	102.80	-6	0.085
Horse	363	38450.27	6.19	33.47	103.06	-3	0.096
Mouse	366	39203.94	5.08	41.16	107.70	-9	0.051
Pig	373	39724.01	5.82	46.83	103.40	-4	0.073
Rabbit	372	39992.29	5.72	52.99	103.33	-5	0.041
Rat	372	40053.85	5.33	40.19	104.11	-9	0.033
Buffalo	373	39756.09	5.84	41.49	101.80	-2	0.099
Cattle	373	39666.79	5.37	41.70	102.06	-5	0.099
Goat	373	39930.28	8.47	35.07	99.71	+4	0.032
Sheep	371	39368.43	5.50	40.27	101.54	-5	0.087
Yak	381	40481.75	5.54	41.63	102.23	-4	0.082

Table 3(on next page)

Table 3. Prediction of signal peptides and properties of the CD14 molecule in mammalian species

Table 3: Prediction of signal peptides and properties of the CD14 molecule in mammalian species

Species	Amino acids size	Cleavage position	Signal site	Probability	Likelihood	Others
Chimpanzee	375	19 and 20	VSA-TT	0.9140	0.9991	0.0009
Gorilla	375	19 and 20	VSA-TT	0.9077	0.9991	0.0009
Human	375	19 and 20	VSA-TT	0.9142	0.9991	0.0009
Monkey	375	19 and 20	VSA-TT	0.9142	0.9991	0.0009
Horse	363	14 and 15	AAT-LE	0.2069	0.675	0.3250
Mouse	366	17 and 18	ASP-AP	0.4563	0.9991	0.0009
Pig	373	19 and 20	VSA-AT	0.7699	0.9989	0.0011
Rabbit	372	19 and 20	AST-DT	0.6574	0.9981	0.0019
Rat	372	17 and 18	VHA-SP	0.8795	0.9998	0.0002
Buffalo	373	20 and 21	VSA-DT	0.9712	0.999	0.0010
Cattle	373	20 and 21	VSA-DT	0.9750	0.9992	0.0008
Goat	373	20 and 21	VTA-DK	0.9642	0.9991	0.0009
Sheep	371	19 and 20	VSA-DT	0.9000	0.9453	0.0547
Yak	381	20 and 21	VSA-DT	0.9752	0.9993	0.0007

Table 4(on next page)

Table 4. Prediction of amino acid consequence at the mutational hotspot of CD14 molecules in mammalian species

Prediction (cutoff= -2.5); values above cutoff are considered deleterious; values below cutoff are considered neutral

1 Table 4 Prediction of amino acid consequence at the mutational hotspot of CD14 molecules in mammalian species

Species	D28V	W45H	G62E	L70D	Q100G	V301M	L318I	G335T	L357H	G370K
Chimpanzee	-3.472	-4.705	-3.154	-3.083	-2.591	-1.905	-1.378	-1.397	-3.088	-2.287
Gorilla	-3.822	-4.651	-3.216	-2.984	-2.554	-2.049	-1.446	-1.397	-3.050	-2.285
Human	-3.679	-4.680	-3.008	-3.056	-2.756	-2.043	-1.445	-1.395	-3.229	-2.305
Monkey	-3.563	-4.782	-3.238	-3.038	-2.758	-1.933	-1.444	-1.293	-3.089	-2.268
Horse	-3.742	-4.914	-3.513	-3.524	-2.364	-1.896	-1.412	-0.983	-2.054	-2.067
Mouse	-3.437	-4.803	-3.408	-1.635	-2.754	-2.009	-1.408	-1.534	-2.437	-1.828
Pig	-3.712	-5.054	-3.702	-1.873	-2.329	-2.013	-1.637	-1.235	-2.902	-2.052
Rabbit	-2.759	-4.293	-2.910	-4.007	-2.744	-1.969	-1.574	-0.544	-1.865	-2.451
Rat	-3.478	-4.725	-3.373	-1.058	-2.905	-2.038	-1.351	0.464	-2.497	-2.619
Buffalo	-3.310	-5.083	-3.497	-3.130	-2.169	-2.064	-1.390	-1.427	-3.065	-2.213
Cattle	-3.289	-5.038	-2.998	-2.991	-2.095	-2.131	-1.385	-1.758	-2.634	-2.191
Goat	-3.919	-4.906	-3.964	-3.390	-2.461	-2.046	-1.476	-0.631	-1.439	-1.601
Sheep	-3.559	-4.952	-4.072	-3.206	-2.312	-1.981	-1.246	-1.376	-2.335	-1.695
Yak	-3.229	-5.036	-3.081	-3.188	-2.233	-2.097	-1.385	-1.575	-2.668	-2.225

2 Prediction (cutoff= -2.5); values above cutoff are considered deleterious; values below cutoff are considered neutral

Figure 1

Figure 1. Multiple sequence alignment of CD14 promoter regions between mammalian species

1	MERASCLLLL	LLP-LVHVSA	TTEPCELD	ED--FRVCVN	FSEQPDWSE	AFQCVSAVEV	EIHAGGLNE	PFLKRVADADA	DPROYADTVK	ALVRRLTVG	AAQVPAQLV	GALRVLAYSR	LKELTIEDLK	
	MGRASCLLLL	LLP-LVHVSA	TTEPCELD	ED--FRVCVN	FSEQPDWSE	AFQCVSAVEV	EIRAGGLNE	PFLKRVADADA	DPROYADTVK	ALVRRLTVG	AAQVPAQLV	GALRVLAYSR	LKELTIEDLK	
	MERASCLLLL	LLP-LVHVSA	TTEPCELD	ED--FRVCVN	FSEQPDWSE	AFQCVSAVEV	EIRAGGLNE	PFLKRVADADA	DPROYADTVK	ALVRRLTVG	AAQVPAQLV	VALRVLAYSR	LKELTIEDLK	
	MERASCLLLL	LLP-LVHVSA	TTEPCELD	ED--FRVCVN	FSEQPDWSE	AFQCVSAVEV	EIRAGGLNE	PFLKRVADADA	DPROYADTVK	ALVRRLTVG	AAQVPAQLV	GALRVLAYSR	LKELTIEDLK	
	MEPVCLLLL	LLP-LIIRAST	TTEPCELD	ED--FRVCVN	FSDQPDWSS	ALQCMQAVQV	EMWGGHSE	PFLRQADYD	DQRYADYVK	ALVRRLTVG	AVQVPAPIL	GVLRVLAYSR	LKELTIEDLK	
	III	LLP-LIIRASA	AIIEPCEVD	EN--FRVCVN	FIGQPDWSS	AFQCMTAVEV	EIRGGGRNE	QFLKAS--A	DPKOYADIVK	ALRLQRLTVG	ANQVPAPIL	ALIRALGYSR	LKELTIEDLK	
	MVCVPYLLLL	LLPSELLRVA	DITEPCELD	DD--FRVCVN	FIDPKPDWSS	AVQCMQAVEV	EISAGGRSE	QFL-K-GADT	NPKOYADTIK	ALVRRLKLG	AAQVPAQLV	AVIRALGYSR	LKELTIEDLK	
	QVCVPYLLLL	LLPSELLRVA	DITEPCELD	DD--FRVCVN	FIDPKPDWSS	AVQCMQAVEV	EISAGGRSE	QFL-K-GADT	NPKOYADTIK	ALVRRLKLG	AAQVPAQLV	AVIRALGYSR	LKELTIEDLK	
	MVCVPYLLLL	LLPPELLRVA	DITEPCELD	DD--FRVCVN	FIDPKPDWSS	AVQCMQAVEV	EISGGGRSE	QFL-K-GADT	NPKOYADTIK	ALVRRLKLG	AAQVPAQLV	AVIRALGYSR	LKELTIEDLK	
	VCVPYLLLL	LLPPELLRVA	DITEPCELD	DD--FRVCVN	FIDPKPDWSS	AVQCMQAVEV	EIRGGHSLD	QFL-K-GVNT	DPKOYADTIK	ALVRRLKLG	AAQVPAQLV	AVIRALGYSR	LKELTIEDLK	
	MVCVPYLLLL	LLPSELLRVA	DREPELD	QH--FRVCVN	FTHQPDWSS	ALQCMQAVEV	EIRGGGRSD	QFL-K-SASA	NPKOYADIMK	ALRLKLTIVG	AAQVPAQLA	LVIRALGYSR	LKELTIEDLK	
	PIG	MVRLPCPLLL	LLP-LIIRASA	ATEPCELD	ED--FRVCVN	FTHQPDWSS	ALQCMQAVEV	EIRGGGRSD	QFL-K-SASA	NPKOYADIMK	ALRLKLTIVG	AAQVPAQLA	LVIRALGYSR	LKELTIEDLK
	RAI	MKMLGGLLL	LLP-LIIRVHASP	ATEPCELD	DESVRCYCN	FSDQPDWSS	AFQCMQAVEV	YLLKRVDETA	NLQYTDIIR	SLRKLTLVR	SARVTPQILF	GTLRVLGYSR	LKELTIEDLK	
	MOUSE	MERYGLLL	L-LIIRVHASP	ATEPCELD	ES--CSN	FSDPKPDWSS	AFNCLGADY	EYFGGRSE	YLLKRVDETA	NLQYTDIIR	SLRKLTLVR	SARVTPQILF	GTLRVLGYSR	LKELTIEDLK
	Consensus	m.....LLLL	Llp.LlvvSA .	tpEPCLD#	#d..frCvCN	FsdqP#WSS	AfQC..Av#V	Ei.gGGRs#	.fL...d..#	p.q\$ad.ik	alvrRLtvg	aaq!Baqliv	..Lrvlgysr	Lkeltie#le
131	IGTGMPLP	LEA-----	-TGLALSSLR	LRNVSWATGR	SWIAELQOWL	KPGLKVLISA	QAHSPAFSC	QVRAPPALIS	LDLSDNPGLG	ERGLIAALCP	HKFPALQNL	LRNTGMETPT	GVCAALAAAG	260
	IGTGMPLP	LEA-----	-TGLALSSLR	LRNVSWATGR	SWIAELQOWL	KPGLKVLISA	QAHSPAFSC	QVRAPPALIS	LDLSDNPGLG	ERGLIAALCP	HKFPALQNL	LRNTGMETPT	GVCAALAAAG	
	IGTGMPLP	LEA-----	-TGLALSSLR	LRNVSWATGR	SWIAELQOWL	KPGLKVLISA	QAHSPAFSC	QVRAPPALIS	LDLSDNPGLG	ERGLIAALCP	HKFPALQNL	LRNTGMETPT	GVCAALAAAG	
	IGTGMPLP	LEA-----	-TGLALSSLR	LRNVSWATGR	SWIAELQOWL	KPGLKVLISA	QAHSPAFSC	QVRAPPALIS	LDLSDNPGLG	ERGLIAALCP	HKFPALQNL	LRNTGMETPT	GVCAALAAAG	
	VTGTAPPPPP	LEA-----	-TGPALSTLS	LRNVSWPKGS	AWLSLQOWL	KPGLQVLINIA	QAHTLAFSC	QVRTSALIT	LDLSENPGLG	ERGLIAALCP	HKFPALQNL	LRNAGMKTLQ	GVCAALAAAG	
	VTGTMPPPP	LEA-----	-TGPPLSSLR	LRNVSWATGS	AWLALQOWL	KPGLKILISA	QAHTLAFSC	QLHSTALIT	LDLSENPGLG	ERGLIAALCP	HKFPALQNL	LRNAGMKTLQ	GVCAALAAAG	
	VTGTPPTPT	LEA-----	-AGPALITLS	LRNVSWITGG	AWLGLQOWL	KPGLRVINIA	QAHTLAFSC	GLSTFALIT	LDLSDNPSLG	DSGLMAALCP	NKFPALQVLA	LRNAGMETPS	GVCAALAAAR	
	YAK	VTGTPPTPT	LEA-----	VTGTPPLK	AWLGLQOWL	KPGLRVINIA	QAHTLAFSC	GLSTFALIT	LDLSDNPSLG	DSGLMAALCP	NKFPALQVLA	LRNAGMETPS	GVCAALAAAR	
	BUFFALO	VTGTPPTPT	LEA-----	-TGPATILS	LRNVSWATGG	AWLGLQOWL	KPGLRVINIA	QAHTLAFSC	GLSTFALIT	LDLSDNPSLG	DTGLMAALCP	NKFPALQVLA	LRNAGMKLS	GVCAALAAAR
	SHEEP	VTGTPPTPT	LEA-----	-TGPATILS	LRNVSWATGG	AWLGLQOWL	KPGLRVINIA	QAHTLAFSC	GLSTFALIT	LDLSDNPSLG	DTGLMAALCP	NKFPALQVLA	LRNAGMKLS	GVCAALAAAR
	GOAT	VTGTPPTPT	LEA-----	-TGPATILS	LRNVSWATGG	AWLGLQOWL	KPGLRVINIA	QAHTLAFSC	GLSTFALIT	LDLSDNPSLG	DTGLMAALCP	NKFPALQVLA	LRNAGMKLS	GVCAALAAAR
	PIG	VTGQVPPPL	QET-----	-PGPALITLR	LRNVSWATGG	AWLGLQOWL	QPSIKVLKVA	QAHTLAFSC	QLRAFPALIT	LDLSDNPGLG	ERGLIAALCP	RKFPALQVLA	LRNAGMETPS	GVCAALAGAG
	RAI	VTGTALSP	LEA-----	-TGPDLNLT	LRNVSWATD	TWLALQOWL	KPGLRVINIA	QAHTLAFSC	QVGFAPALIT	LDLSDNPGLG	ERGLIAALCP	RKFPALQVLA	LRNAGMETPS	GVCAALAAAR
	MOUSE	VTGTAPPLP	LEA-----	-TGPDLNLT	LRNVSWATD	TWLALQOWL	KPGLRVINIA	QAHTLAFSC	QVGFAPALIT	LDLSDNPGLG	ERGLIAALCP	RKFPALQVLA	LRNAGMETPS	GVCAALAAAR
	Consensus	!GTc.pppp. l#a	cGpal.ctl.	LRNVSWatgg	awLaELQOWL	kPglKvLs!A	Qahs!AFc.	qvr.Fpalitc	LDLs#NpGLG	#rSL.aALCP	hKFPalq.lA	LRNagmetps	GVcAa\$Aaag	
261	VQPHSLDLSH	NSLRATVNS	APRCMSSAL	NSLINSFAGL	EQVPKGLPAK	LRVLIDLSNR	LRNAPDDEL	FEVDNLITDG	NPFLVPGTAL	PHGSMNSGV	VFACARSILS	VGVSGLTIVL	QGARGFA	387
	VQPHSLDLSH	NSLRATVNS	APRCMSSAL	NSLINSFAGL	EQVPKGLPAK	LRVLIDLSNR	LRNAPDDEL	FEVDNLITDG	NPFLVPGTAL	PHGSMNSGV	VFACARSILS	VGVSGLTIVL	QGARGFA	
	VQPHSLDLSH	NSLRATVNS	APRCMSSAL	NSLINSFAGL	EQVPKGLPAK	LRVLIDLSNR	LRNAPDDEL	FEVDNLITDG	NPFLVPGTAL	PHGSMNSGV	VFACARSILS	VGVSGLTIVL	QGARGFA	
	VQPHSLDLSH	NSLRATVNS	APRCMSSAL	NSLINSFAGL	EQVPKGLPAK	LRVLIDLSNR	LRNRPDDEL	QVDMNLADG	NPFLVPGTAL	PHGSMNSGV	VFACARSILS	VGVSGLTIVL	QGARGFA	
	VQPHSLDLSH	NSLRATQ--	--RCIMPSAL	NSLINSFTGL	QVQPKGLPAK	LRVLIDLSNR	LRNAPDDEL	PKVNSLIDR	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRATA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	PKVNSLIDR	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NSLRVTA--	PG	ATRCVMPSPAL	NSLINSFAGL	EQVPKGLPAK	LRNAPDDEL	FEVDNLITDG	NPFLVPDPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	QVQPKGLPAK	
	VQPHSLDLSH	NS												

Figure 2

Figure 2: Phylogenetic tree of evolutionary relationships among taxa

The evolutionary history was inferred using the Neighbor-Joining method. The optimal tree with the sum of branch length = 1.48602764. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the p-distance method and are in the units of the number of amino acid differences per site. The analysis involved 14 amino acid sequences. The coding data were translated assuming a standard genetic code table.




Figure 3

Figure 3: Comparison of predicted intra-domain features of CD14 protein

This comparison shows showing leucine-rich repeat (PS51450), which provide additional information about the structure and function of critical amino acids in 14 mammalian species analyzed




Figure 4

Figure 4: Conserved domain LRR patterns across mammalian species

HUMAN	KRVLDLSON.R.LNRAPQPDEL
RAT	AATLDLSDNpE.LGERGLISALC
RAT_2	PQALDLSEN.S.LRDTAGTPSCD
RAT_3	KSVLDLSYN.R.LDRKPRPEELP
RAT_4	QNSNLSFT.G.LDHVPKGLPA-
MOUSE	AATLDLSDNpE.LGERGLISALC
MOUSE_2	QACGLDSEN.S.LRDAAGAPSCD
MOUSE_3	KSVLDLSYN.R.LDRNPSPEL
BOVINE	AATLDLSDN.PsLGDSGLMAALC
BOVINE_2	QPQSLDSEN.S.LRVTA PGATRC
BOVINE_3	KSVLDLSON.K.LSREPRDEL
GOAT	AATLDLSDN.PsLGDSGLMAALC
GOAT_2	QPQNLDSEN.S.LRVTA PGATRC
GOAT_3	KSVLDLSON.K.LSREPRDEL
MONKEY	AATLDLSDN.PsLGERGLIAALC
MONKEY_2	KRVLDLSON.R.LNRRPRDEL
GORILLA	AATLDLSDN.PsLGERGLIAALC
GORILLA_2	KRVLDLSON.R.LNRAPQPDEL
SHEEP	AATLDLSDN.PsLGDSGLMAALC
SHEEP_2	QPQSLDSEN.S.LRVTPGATRCV
SHEEP_3	KSVLDLSON.K.LSREPRDEL
PIG	AATLDLSDN.P.LGERGLTAAL
PIG_2	KRVLDLSON.K.LNRAPRPEEL
BUFFALO	AATLDLSDN.PsLGD TGMAALC
BUFFALO_2	QPQSLDSEN.S.LRVTA PGATRC
BUFFALO_3	KSVLDLSON.K.LSREPRDEL
CHIMPANZEE	AATLDLSDNpE.LGERGLIAALC
CHIMPANZEE_2	KRVLDLSON.R.LNRAPQPDEL
YAK	AATLDLSDNpE.LGERGLIAALC
YAK_2	QPQSLDSEN.S.LRVTA PGATRC
YAK_3	KSVLDLSON.K.LSREPRDEL
HORSE	AATLDLSDNpE.LGERGLIAALC
HORSE_2	KSVLDLSON.R.LNRAPRDEL

Figure 5

Figure 5: CD14 protein sequence logo displaying the most conserved domain and the positions of amino acids

Sequence logo displaying the most conserved domain and the positions of amino acids starting from the N-terminus on the left to C-terminus to the right. The relative frequency of the amino acids is shown on the y-axis.




Figure 6

Fig 6. Hierarchical tree-predicted subcellular localizations of CD14 protein using neural network algorithm

6a: Hierarchical tree for all other mammalian species analyzed

6b: Hierarchical tree for sheep only




Figure 6a




Figure 6b

Figure 7

Figure 7. The network view of predicted associations for group of proteins with CD14

The network nodes are proteins. The edges represent the predicted functional associations. The thickness of the line indicate the degree of confidence prediction for the interaction.

Red line: fusion evidence

Green line: neighborhood evidence

Blue line: co-occurrence evidence

Purple line: experimental evidence

Yellow line: text mining evidence

Light blue line: database evidence

Black line: co-expression evidence




Figure 8

Figure 8: Venn diagram showing the proportion of intersection and unique genes depicting evolutionary diversity of CD14 molecule

8a: Comparison and visualization of protein interaction with CD14 molecule in pig, rabbit, mouse and rat

8b: Comparison and visualization of protein interaction with CD14 molecule in cattle, yak, sheep, goat and buffalo

8c: Comparison and visualization of protein interaction with CD14 molecule in human, gorilla, chimpanzee and monkey




Figure 8a




Figure 8b




Figure 8c